These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 34497376)

  • 1. Neutralizing antibodies for the prevention and treatment of COVID-19.
    Du L; Yang Y; Zhang X
    Cell Mol Immunol; 2021 Oct; 18(10):2293-2306. PubMed ID: 34497376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV.
    Jiang W; Wang J; Jiao S; Gu C; Xu W; Chen B; Wang R; Chen H; Xie Y; Wang A; Li G; Zeng D; Zhang J; Zhang M; Wang S; Wang M; Gui X
    MAbs; 2021; 13(1):1953683. PubMed ID: 34313527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralizing Monoclonal Antibodies Inhibit SARS-CoV-2 Infection through Blocking Membrane Fusion.
    Li CJ; Chao TL; Chang TY; Hsiao CC; Lu DC; Chiang YW; Lai GC; Tsai YM; Fang JT; Ieong S; Wang JT; Chang SY; Chang SC
    Microbiol Spectr; 2022 Apr; 10(2):e0181421. PubMed ID: 35293796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of human anti-spike protein receptor binding domain antibodies on severe acute respiratory syndrome coronavirus neutralization escape and fitness.
    Sui J; Deming M; Rockx B; Liddington RC; Zhu QK; Baric RS; Marasco WA
    J Virol; 2014 Dec; 88(23):13769-80. PubMed ID: 25231316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The development of neutralizing antibodies against SARS-CoV-2 and their common features.
    Liu LD; Lian C; Yeap LS; Meng FL
    J Mol Cell Biol; 2020 Nov; 12(12):980-986. PubMed ID: 33377928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern.
    Deshpande A; Harris BD; Martinez-Sobrido L; Kobie JJ; Walter MR
    Front Immunol; 2021; 12():691715. PubMed ID: 34149735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current Status and Perspectives of Therapeutic Antibodies Targeting the Spike Protein S2 Subunit against SARS-CoV-2.
    Yamamoto Y; Inoue T
    Biol Pharm Bull; 2024; 47(5):917-923. PubMed ID: 38692869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epitope Analysis of Anti-SARS-CoV-2 Neutralizing Antibodies.
    Xue JB; Tao SC
    Curr Med Sci; 2021 Dec; 41(6):1065-1074. PubMed ID: 34606064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants.
    Haslwanter D; Dieterle ME; Wec AZ; O'Brien CM; Sakharkar M; Florez C; Tong K; Rappazzo CG; Lasso G; Vergnolle O; Wirchnianski AS; Bortz RH; Laudermilch E; Fels JM; Mengotto A; Malonis RJ; Georgiev GI; Quiroz JA; Wrapp D; Wang N; Dye KE; Barnhill J; Dye JM; McLellan JS; Daily JP; Lai JR; Herbert AS; Walker LM; Chandran K; Jangra RK
    mBio; 2021 Oct; 12(5):e0247321. PubMed ID: 34607456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies.
    Yan R; Wang R; Ju B; Yu J; Zhang Y; Liu N; Wang J; Zhang Q; Chen P; Zhou B; Li Y; Shen Y; Zhang S; Tian L; Guo Y; Xia L; Zhong X; Cheng L; Ge X; Zhao J; Wang HW; Wang X; Zhang Z; Zhang L; Zhou Q
    Cell Res; 2021 May; 31(5):517-525. PubMed ID: 33731853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2 spike S2-specific neutralizing antibodies.
    Li CJ; Chang SC
    Emerg Microbes Infect; 2023 Dec; 12(2):2220582. PubMed ID: 37254830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein structure analysis of the interactions between SARS-CoV-2 spike protein and the human ACE2 receptor: from conformational changes to novel neutralizing antibodies.
    Mercurio I; Tragni V; Busto F; De Grassi A; Pierri CL
    Cell Mol Life Sci; 2021 Feb; 78(4):1501-1522. PubMed ID: 32623480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Binding and neutralizing abilities of antibodies towards SARS-CoV-2 S2 domain.
    Gao X; Fan L; Zheng B; Li H; Wang J; Zhang L; Li J; Zhu F
    Hum Vaccin Immunother; 2022 Nov; 18(5):2055373. PubMed ID: 35417303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of high affinity monoclonal antibodies against SARS-CoV-2 variant infection using a DNA prime-protein boost strategy.
    Chiang CY; Chen MY; Hsu CW; Liu CY; Tsai YW; Liao HC; Yan JY; Chuang ZS; Wang HI; Pan CH; Yu CY; Yu GY; Liao CL; Liu SJ; Chen HW
    J Biomed Sci; 2022 Jun; 29(1):37. PubMed ID: 35681239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Monoclonal Antibodies and Recombined Antibodies Against Variant SARS-CoV-2.
    Xie J; Ding C; He J; Zhang Y; Ni S; Zhang X; Chen Q; Wang J; Huang L; He H; Li W; Ma H; Jin T; Zhang S; Gao Y
    Front Immunol; 2021; 12():715464. PubMed ID: 34539645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants.
    Yang Z; Wang Y; Jin Y; Zhu Y; Wu Y; Li C; Kong Y; Song W; Tian X; Zhan W; Huang A; Zhou S; Xia S; Tian X; Peng C; Chen C; Shi Y; Hu G; Du S; Wang Y; Xie Y; Jiang S; Lu L; Sun L; Song Y; Ying T
    Signal Transduct Target Ther; 2021 Nov; 6(1):378. PubMed ID: 34732694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants.
    Tai W; Wang Y; Fett CA; Zhao G; Li F; Perlman S; Jiang S; Zhou Y; Du L
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Bifluorescent-Based Assay for the Identification of Neutralizing Antibodies against SARS-CoV-2 Variants of Concern
    Chiem K; Morales Vasquez D; Silvas JA; Park JG; Piepenbrink MS; Sourimant J; Lin MJ; Greninger AL; Plemper RK; Torrelles JB; Walter MR; de la Torre JC; Kobie JK; Ye C; Martinez-Sobrido L
    J Virol; 2021 Oct; 95(22):e0112621. PubMed ID: 34495697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern.
    Yuan M; Chen X; Zhu Y; Dong X; Liu Y; Qian Z; Ye L; Liu P
    J Virol; 2022 Aug; 96(16):e0077522. PubMed ID: 35916510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.